Jaguar Health, Inc. Stock News

NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com

Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive

Jaguar Health Inc (JAGX) shares closed today at 1.6% above its 52 week low of $0.92, giving the company a market cap of $43M. The stock is currently down 10.1% year-to-date, down 92.2% over the past 12 months, and down 100.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 79.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 224.1% The company's stock price performance over the past 12 months lags the peer average by 302.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Jaguar Health Inc (JAGX) shares closed today at 1.6% above its 52 week low of $0.92, giving the company a market cap of $43M. The stock is currently down 8.5% year-to-date, down 84.2% over the past 12 months, and down 100.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 79.9% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.7% lower than its 5-day moving average, 15.8% lower than its 20-day moving average, and 48.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 106.2% The company's stock price performance over the past 12 months lags the peer average by 237.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Jaguar Health, Inc. (NASDAQ:JAGX) saw unusually large options trading activity on Tuesday. Traders acquired 9,504 call options on the stock. This represents an increase of 1,059% compared to the average volume of 820 call options. NASDAQ:JAGX opened at $1.18 on Thursday. Jaguar Health has a fifty-two week low of $1.05 and a fifty-two week high [] The post Jaguar Health Target of Unusually Large Options Trading (NASDAQ:JAGX) appeared first on ETF Daily News .

NEW YORK , Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, ALLK, PTPI, OSCR, and JAGX. Full story available on Benzinga.com

By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / A

(PR-inside.com) By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today shared the following quote from the press release the U.S. Food and Drug Administration (FDA) issued December 21, 2021: "Diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. Chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for ..

Jaguar Health, Inc. (NASDAQ:JAGX) with the stream of 20.00% also noticed, India Snap Inc. (NYSE:SNAP) encountered a rapid change of 3.78% in the last hour of Tuesdays trading session. Jaguar The post Top RSI Trades for the day: Jaguar Health, Inc. (NASDAQ:JAGX), Snap Inc. (NYSE:SNAP) appeared first on Stocks Equity .

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 20% in the most recent trading session. This is why it happened.

The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs. This is the firs

Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment.

(PR-inside.com) By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it received conditional approval to market Canalevia-CA1 (crofelemer delayed-release tablets), Jaguar''s oral plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. This is the first and only product indicated for the treatment of chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from FDA. According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some ..

By prescription only, Canalevia -CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 21, 2021 / Jaguar Health, Inc.

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.